



Preferred Drug List

NEW DRUG REVIEW

Proprietary Name: Vyvanse™

Common Name: Lisdexamfetamine Dimesylate

PDL Category: Stimulants

<u>Comparable Products</u>	<u>Preferred Drug List/ Recommended Drug List Status</u>
Dexedrine®	Preferred
Strattera®	Non-Recommended

Summary

Indications and Usage: Attention Deficit Hyperactivity Disorder

Mechanism of Action: Exact mechanism of action unknown; lisdexamfetamine is a prodrug of dextroamphetamine that is converted following absorption in the GI tract. Amphetamines are thought to work by stimulating CNS activity, blocking reuptake of and increasing the release of norepinephrine and dopamine

Dosage Forms: Capsules; 30mg, 50mg, and 70mg

Recommended Dosage: For children 6 – 12 years old: start 30mg once daily in the morning; increase dose in increments of 20mg/day each week.

Common Adverse Drug Reactions: Anorexia, insomnia, nausea, and irritability

Contraindications: Previous hypersensitivity to any component of the product, advanced arteriosclerosis, CVD, HTN, hyperthyroidism, glaucoma, patients with a history of drug abuse

Manufacturer: Shire & New River Pharmaceuticals Inc.

Analysis: Vyvanse™ is a prodrug of dextroamphetamine that is converted in the GI tract following oral administration. The drug has scored lower than dextroamphetamine on the Drug Liking Effects scale at equivalent doses, however, the DEA has classified Vyvanse™ as a Schedule II controlled substance. Atomoxetine, the only non-stimulant medication approved for ADHD, was shown in clinical trials to not be associated with a pattern of response that suggested stimulant or euphoriant properties when compared to placebo and had only isolated incidents of drug diversion or inappropriate self-administration. In clinical studies, using the ADHD-RS, 30, 50, and 70mg doses of Vyvanse™ demonstrated a 21.8, 23.4, and 26.7 point reduction from baseline respectively. By comparison, atomoxetine has reported a 12.8 to 16.7 mean decrease from baseline on the ADHD-RS. Vyvanse™ has not yet been compared to other available stimulant products in Phase III trials. Vyvanse™ is no more costly than other preferred and recommended long-acting stimulants on the Preferred and Recommended Drug List. Therefore, it is recommended that Vyvanse™ be added to the Recommended Drug List as a Recommended Drug.

IME Recommendation:

- | | |
|---|--|
| <input type="checkbox"/> Preferred Drug | <input checked="" type="checkbox"/> Recommended Drug |
| <input type="checkbox"/> Non-Preferred Drug | <input type="checkbox"/> Non-Recommended Drug |
| <input type="checkbox"/> Preferred Drug with Conditions | |